ACRV · Acrivon Therapeutics Inc
United States · RS rating 46 · As of 2026-10-14
| Price | 1.72 USD |
|---|---|
| 1-day change | -1.7% |
| RS rating (overall / 1M / 3M / 12M) | 46 / 33 / 56 / 40 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 26 / 23 / 27 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +12.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +42.9% |
| Market cap (USD) | $73.2M |